Scholarlink

Purpose <p>Intrahepatic cholangiocarcinoma (iCCA) has been a contraindication for liver transplantation due to frequent recurrence and poor survival. We sought to determine the true proportion of transplantation-eligible iCCA patients and their outcomes without transplantation.</p> Methods <p>Data from patients evaluated for iCCA at two academic medical centers between 2008 and 2018 were analyzed retrospectively. Overall survival was determined for patients categorized as eligible for liver transplantation based on six criteria: unresectability, no extrahepatic disease, stable disease after chemotherapy, functional status (maximum age, 72 years), no major comorbidity, and no involvement of major vasculature.</p> Results <p>Of 1407 iCCA patients with sufficient data, 327 (23%) had advanced liver-confined disease. Most (n = 180 [55%]) progressed or died before 6 months of therapy. Others were ineligible owing to resection after pretreatment (n = 47), poor performance status (n = 8), advanced age (n = 32), comorbidity (n = 19), or extensive extrahepatic vascular involvement (n = 2). Only 39 patients (12% of 327; 2.8% of 1,407; 95% confidence interval [CI] 2–3.8%) met eligibility, with more than half (n = 22 [56%]) treated with hepatic arterial infusion pump chemotherapy. Their median survival from diagnosis was 39 months (95% CI 28–62 months); 3-year survival from estimated eligibility was 46% (95% CI 32–65%).</p> Conclusions <p>Patients who meet stringent eligibility criteria for liver transplantation constitute approximately 3% of patients with iCCA. The observed survival exceeds benchmarks established for systematic therapy alone and is likely attributable to favorable tumor biology and hepatic artery infusion chemotherapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Eligibility for Liver Transplantation in Patients with Intrahepatic Cholangiocarcinoma

  • 期刊论文

  • 发表日期：

    2026年4月16日

查看全文
  • Lauren E. Schleimer,
  • Merve Rousian,
  • Remo Alessandris,
  • Hannah L. Kalvin,
  • Edoardo Poletto,
  • Joshua S. Jolissaint,
  • Victorien van Verschuer,
  • Vinod P. Balachandran,
  • Jeffrey Drebin,
  • Michael I. D’Angelica,
  • Jeroen de Jonge,
  • T. Peter Kingham,
  • Wojciech Polak,
  • Robert J. Porte,
  • Kevin C. Soares,
  • Alice C. Wei,
  • Mithat Gonen,
  • William R. Jarnagin,
  • Bas Groot Koerkamp

摘要

Purpose

Intrahepatic cholangiocarcinoma (iCCA) has been a contraindication for liver transplantation due to frequent recurrence and poor survival. We sought to determine the true proportion of transplantation-eligible iCCA patients and their outcomes without transplantation.

Methods

Data from patients evaluated for iCCA at two academic medical centers between 2008 and 2018 were analyzed retrospectively. Overall survival was determined for patients categorized as eligible for liver transplantation based on six criteria: unresectability, no extrahepatic disease, stable disease after chemotherapy, functional status (maximum age, 72 years), no major comorbidity, and no involvement of major vasculature.

Results

Of 1407 iCCA patients with sufficient data, 327 (23%) had advanced liver-confined disease. Most (n = 180 [55%]) progressed or died before 6 months of therapy. Others were ineligible owing to resection after pretreatment (n = 47), poor performance status (n = 8), advanced age (n = 32), comorbidity (n = 19), or extensive extrahepatic vascular involvement (n = 2). Only 39 patients (12% of 327; 2.8% of 1,407; 95% confidence interval [CI] 2–3.8%) met eligibility, with more than half (n = 22 [56%]) treated with hepatic arterial infusion pump chemotherapy. Their median survival from diagnosis was 39 months (95% CI 28–62 months); 3-year survival from estimated eligibility was 46% (95% CI 32–65%).

Conclusions

Patients who meet stringent eligibility criteria for liver transplantation constitute approximately 3% of patients with iCCA. The observed survival exceeds benchmarks established for systematic therapy alone and is likely attributable to favorable tumor biology and hepatic artery infusion chemotherapy.